Breaking News on Supplements & Nutrition - North AmericaEU edition

News > Markets

Nutrition Facts overhaul is a missed opportunity for long chain omega-3s EPA and DHA, says GOED

Post a comment

By Elaine Watson+

Last updated on 06-Aug-2014 at 03:39 GMT

GOED 'respectfully disagrees' with the FDA over its assessment of the evidence supporting the benefits of EPA and DHA
GOED 'respectfully disagrees' with the FDA over its assessment of the evidence supporting the benefits of EPA and DHA

The FDA’s overhaul of the Nutrition Facts panel misses a public health opportunity by prohibiting firms from evening highlighting long chain omega-3 fatty acids EPA and DHA on the panel on a voluntary basis, says GOED, the Global Organization for EPA and DHA Omega‐3s.

While the FDA notes that a review it conducted in 2004 found there was “supportive, but not conclusive, research” to suggest EPA and DHA may reduce the risk of coronary heart disease, it says listing them on the Nutrition Facts panel is not very useful because there are no established dietary reference intakes (DRIs) for EPA and DHA, while their role in reducing chronic disease risk is not “well-established”.

Growing body of evidence supports the cardiovascular benefits of EPA and DHA

But the data suggests otherwise, according to regulatory & scientific affairs VP Harry B. Rice, PhD: “Given that the last authoritative scientific review of EPA and DHA was over ten years ago… GOED respectfully disagrees that there is a ‘lack of well-established evidence for a role of n-3 … polyunsaturated fatty acids in chronic disease risk’.

In fact, a large and growing body of evidence supports the cardiovascular benefits of EPA and DHA, says Dr Rice, while at 113mg/day, US intakes of EPA and DHA are well below recommendations in the Dietary Guidelines for Americans (250mg/day).

In a formal comment  on the FDA proposals - which among other things recommend removing vitamins A and C as mandatory listed micronutrients and replacing them with vitamin D and potassium - GOED urges the agency to at least include EPA and DHA on the list of ‘non-statutory nutrients’ firms will be allowed to list on the panel on a voluntary basis.

US intakes of EPA and DHA are well below recommendations in the Dietary Guidelines

As the FDA (click HERE ) itself notes, says Dr Rice, “The 2010 Dietary Guidelines Advisory Committee concluded that moderate evidence shows that the consumption of two servings of seafood per week, which provides an average of 250 mg/day of EPA and DHA is associated with reduced cardiac mortality from coronary heart disease or sudden deaths, both in persons with and without cardiovascular disease.”

Indeed, the first sentence of the ‘Nutrients of Concern’ section of the guidelines says that intakes of seafood - a key source of EPA & DHA - are lower than recommended, and that as a result, intakes of some nutrients are ‘low enough to be of public health concern’, he points out.

“Specifically, the article cited as the source of evidence regarding EPA and DHA supplementation by the Nutrient Adequacy Subcommittee concluded that ‘National public health initiatives to increase omega-3 fatty acid consumption are needed; the working group believes that data are currently sufficient to indicate that intake of omega-3 fatty acids is suboptimal, and a national and international initiative should be launched to shift omega-3 fatty acid intake upward.”

While simply listing EPA and DHA on nutrition facts labels will not in itself boost intakes, he acknowledges, it will “go a long way to assist consumers in maintaining healthy dietary practices”.

Technological advances have made adding lc omega-3s to foods and beverages easier

The FDA recently frustrated many players in the omega-3 industry by publishing a final rule prohibiting certain nutrient content claims about EPA and DHA on food labels on the grounds that no reference levels have been established for these nutrients.  

However, there is still enthusiasm for adding long chain omega-3s to food and beverage products, with firms such as Cargill recently introducing a cost-effective ‘drop-in’ solution for food & beverage EPA/DHA fortification called IngreVita .

Meanwhile, Virun has developed patented technology enabling the inclusion of EPA+DHA (which are prone to oxidation, causing taste, odor and stability problems) in clean label shelf-stable foods and beverages at unprecedented levels.

According to GOED estimates, volumes of algal DHA used in infant formula rose in 2013, while volumes of EPA and DHA of marine origin used in other food products (primarily from fish oil, but also algal omega-3s) were fairly flat.

Think you need to pop pills to get a decent dose of omega-3? Think again

Click HERE to read all the comments in the docket on the FDA Nutrition Facts proposal. 

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products

Key Industry Events


Access all events listing

Our events, Events from partners...